Galimi, Francesco

A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 939

Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 657

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3

Sun, C., Hobor, S., Bertotti, A., Zecchin, D., Huang, S., Galimi, F., Cottino, F., Prahallad, A., Grernrum, W., Tzani, A., et al. (2014) · Cell Reports

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 304

HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment

Kavuri, S. M., Jain, N., Galimi, F., Cottino, F., Leto, S. M., Migliardi, G., Searleman, A. C., Shen, W., Monsey, J., Trusolino, L., et al. (2015) · Cancer Discovery

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 302

Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates

Solinas, G., Naugler, W., Galimi, F., Lee, M.-S., & Karin, M. (2006) · Proceedings of the National Academy of Sciences

Pancreatic function and diabetesAdipokines, Inflammation, and Metabolic Diseases

Cited by 284

Fate of endogenous stem/progenitor cells following spinal cord injury

Horky, L. L., Galimi, F., Gage, F. H., & Horner, P. J. (2006) · Journal of Comparative Neurology

Neurogenesis and neuroplasticity mechanismsSpinal Cord Injury Research

Cited by 258

Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas

Migliardi, G., Sassi, F., Torti, D., Galimi, F., Zanella, E. R., Buscarino, M., Ribero, D., Muratore, A., Massucco, P., Pisacane, A., et al. (2012) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesPI3K/AKT/mTOR signaling in cancer

Cited by 191

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

PDXNET Consortium, Woo, X. Y., EurOPDX Consortium, Giordano, J., Srivastava, A., Zhao, Z.-M., Lloyd, M. W., de Bruijn, R., Suh, Y.-S., Patidar, R., et al. (2021) · Nature Genetics

Cancer Genomics and DiagnosticsGenomic variations and chromosomal abnormalities

Cited by 190

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies

Zanella, E. R., Galimi, F., Sassi, F., Migliardi, G., Cottino, F., Leto, S. M., Lupo, B., Erriquez, J., Isella, C., Comoglio, P. M., et al. (2015) · Science Translational Medicine

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 117

Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype

Lupo, B., Sassi, F., Pinnelli, M., Galimi, F., Zanella, E. R., Vurchio, V., Migliardi, G., Gagliardi, P. A., Puliafito, A., Manganaro, D., et al. (2020) · Science Translational Medicine

Colorectal Cancer Treatments and StudiesCancer Cells and Metastasis

Cited by 83

T cell tyrosine phosphorylation response to transient redox stress

Secchi, C., Carta, M., Crescio, C., Spano, A., Arras, M., Caocci, G., Galimi, F., La Nasa, G., Pippia, P., Turrini, F., et al. (2015) · Cellular Signalling

Redox biology and oxidative stressNeutrophil, Myeloperoxidase and Oxidative Mechanisms

Cited by 10